Prurigo nodularis (PN) is a subtype of chronic prurigo that is highly pruritic, chronic, difficult to treat and associated with high disease burden.  The pathogenesis of PN is not completely understood, although inflammatory pathways have strongly implicated the involvement of IL-31.  Nemolizumab is a humanised monoclonal antibody targeting the IL-31 receptor alpha subunit that is under development for treatment of severe pruritic skin diseases.
Nemolizumab resulted in a rapid and clinically relevant improvement of pruritus and nodular lesions in PN with onset of effect on pruritus as early as week 1 with 38% of patients clear or almost clear of skin lesions.
Nemolizumab was significantly more effective than placebo in all clinical endpoints
Nemolizumab was well tolerated with a similar safety profile vs placebo.
Key messages/Clinical perspectives
Nemolizumab demonstrated highly encouraging results compared to placebo in treatment of PN in phase II trials, warranting additional studies.
Presenter disclosure information: S Ständer: has received research funds from DFG, EADV, BMBF, and IZKF and has served as a consultant for Almirall, Bayer, Beiersdorf, Bellus Health, Bionorica, Cara Therapeutics, Celgene, DS Biopharma, Galderma, Kneipp, Maruho, Menlo Therapeutics, Marz, NeRRe Therapeutics, Novartis, Nuformix, Perrigo, Sienna Therapeutics, ACO HUD Nordic, Toray, Trevi Therapeutics and as an investigator for Dermasence, Galderma, Kiniksa, Menlo Therapeutics, Trevi Therapeutics, Novartis, Sanofi, Vanda Therapeutics.
Presented by: Prof. Kristian Reich, Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, and Skinflammation® Center, Hamburg, Germany